Advertisement

Molecular Medicine

, Volume 20, Supplement 1, pp S7–S9 | Cite as

TNF Antagonists Opened the Way to Personalized Medicine in Rheumatoid Arthritis

  • Ferry Breedveld
Retrospective

Abstract

Rheumatoid arthritis (RA) is an autoimmune disease resulting from a largely unknown interaction between genetically determined and environmental factors. Progress in the understanding of this chronic inflammation in the synovial lining of joints has led to the insight that one cytokine, tumor necrosis factor (TNF), has an important role. This insight started the development of a series of targeted and highly effective therapeutics for RA and a range of other autoinflammatory diseases. RA has changed from a severely debilitating disease into a disease where progression can be stopped in most of the patients.

References

  1. 1.
    Tracey KJ, Vlassara H, Cerami A. (1989) Cachectin/tumor necrosis factor. Lancet. 333:1122–6.CrossRefGoogle Scholar
  2. 2.
    Brennan FM, Jackson A, Chantry D, Maini R, Feldmann M. (1989) Inhibitory effect of TNF α antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet. 334:244–7.CrossRefGoogle Scholar
  3. 3.
    Elliott MH, et al. (1993) Treatment of rheumatoid arthritis with a chimeric monoclonal antibody to tumor necrosis factor α. Arthritis Rheum. 36:1681–90.CrossRefGoogle Scholar
  4. 4.
    Lipsky PE, et al. (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. N. Engl. J. Med. 343:1594–602.CrossRefGoogle Scholar
  5. 5.
    Van Dongen H, et al. (2007) Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double blind, randomized, placebo-controlled trial. Arthritis Rheum. 56:1424–32.CrossRefGoogle Scholar
  6. 6.
    Goekoop-Ruiterman YP, et al. (2007) Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 146:406–15.CrossRefGoogle Scholar
  7. 7.
    Verstappen SM, et al. (2007) Intensive treatment with methotrexate in early rheumatoid arthritis; aiming for remission. Ann. Rheum. Dis. 66:1443–9.CrossRefGoogle Scholar
  8. 8.
    Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. (2007) New therapies for treatment of rheumatoid arthritis. Lancet. 370:1861–74.CrossRefGoogle Scholar
  9. 9.
    Goekoop-Ruiterman YPM, et al. (2010) DAS driven therapy versus routine care in patients with recent onset active RA. Ann. Rheum. Dis. 69:65–69.CrossRefGoogle Scholar
  10. 10.
    Goekoop-Ruiterman YPM, et al. (2007) Patient preferences for treatment: report from a randomized comparison of treatment strategies Ann. Rheum. Dis. 66:1227–32CrossRefGoogle Scholar
  11. 11.
    Van den Hout WB, et al. (2009) Cost utility analysis of treatment strategies in patients with early rheumatoid arthritis. Arthritis Rheum. 61:291–9.CrossRefGoogle Scholar
  12. 12.
    Van der Kooy SM, et al. (2009) Clinical and radiological efficacy of initial versus deluged treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis Ann. Rheum. Dis. 68:1153–8.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2014

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Authors and Affiliations

  1. 1.Leiden University Medical CenterLeidenThe Netherlands

Personalised recommendations